Xeris Biopharma Holdings (XERS) Other financing activities (2020 - 2026)

Xeris Biopharma Holdings (XERS) has reported Other financing activities for 7 consecutive years, with $600000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other financing activities fell 38.27% year-over-year to $600000.0; the trailing twelve-month figure through Jun 2026 stood at $13.7 million (up 114.83% YoY), and the FY2025 full-year result was $11.6 million, up 830.71% from the prior year.
• Other financing activities slipped to $600000.0 in Q2 2026 per XERS's latest filing, from $7.3 million in the prior quarter.
• Across five years, Other financing activities topped out at $7.3 million in Q1 2026 and bottomed at $8000.0 in Q1 2022.
• Historically, Other financing activities has averaged $1.7 million across 5 years, with a median of $549000.0 in 2023.
• The sharpest annual moves came in 2022 and 2025: Other financing activities tumbled 69.23% in 2022, then surged 959.04% in 2025.
• Over 5 years, Other financing activities stood at $318000.0 in 2022, then surged by 72.64% to $549000.0 in 2023, then decreased by 2.73% to $534000.0 in 2024, then rose by 9.36% to $584000.0 in 2025, then grew by 2.74% to $600000.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $600000.0, $7.3 million, and $584000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.